Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Fosun Pharma and SIMM to Co-Develop Oncology Drug

publication date: Nov 27, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Fosun Pharma and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, have agreed to jointly develop an innovative, small-molecule, triple-target oncology drug. The two entities will share the risk, the patent and benefits, though specific details of the arrangement were not disclosed. Fosun’s share of the research will be carried out by Chongqing Fochon Pharma, a subsidiary founded in 2009 by Dr. Weibo Wang. More details....

Stock Symbol: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners